Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells

Molecular Cancer Therapeutics

Volumn 7, Issue 5, 2008, Pages 1218-1226

  Alfano, Randall W ^a,b   Leppla, Stephen H ^c   Liu, Shihui ^c   Bugge, Thomas H ^d   Herlyn, Meenhard ^e   Smalley, Keiran S ^e   Bromberg White, Jennifer L ^f   Duesbery, Nicholas S ^f   Frankel, Arthur E ^a,b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e WISTAR INSTITUTE   (United States)

^f VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; B RAF KINASE; BETA LACTAMASE; GELATINASE A; GELATINASE B; HYBRID PROTEIN; LETHAL FACTOR PROTEIN; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BACTERIAL ANTIGEN; BACTERIAL TOXIN; GELATINASE; MATRIX METALLOPROTEINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SPECIFICITY; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE MUTATION; HUMAN; HUMAN CELL; LETHAL GENE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; CELL CULTURE; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; TUMOR CELL LINE;

ANTIGENS, BACTERIAL; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL LINE, TUMOR; GELATINASES; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR CELLS, CULTURED;

EID: 49849093232     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0024     Document Type: Article

References (30)

1. Queirolo P, Acquati M. Targeted therapies in melanoma. Cancer Treat Rev 2006;32:524-31.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
3. Hofmann UB, Houben R, Bröcker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005;87:307-14.
4. Denkert C, Siegert A, Leclere A, Turzynski A, Hauptmann S. An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells. Clin Exp Metastasis 2002;19:79-85.
5. Duesbery NS, Resau J, Webb CP, et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 2001;98:4089-94.
6. Young JA, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007;76:243-65.
7. Puhar A, Montecucco C. Where and how do anthrax toxins exit endosomes to intoxicate host cells? Trends Microbiol 2007;15:477-82.
8. Chopra AP, Boone SA, Liang X, Duesbery NS. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem 2003;278:9402-6.
9. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A 2002;99:3052-7.
10. Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 2005;4:1303-10.
11. Liu S, Wang H, Currie BM, et al. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem 2008;283:529-40.
12. Chen KH, Liu S, Bankston LA, Liddington RC, Leppla SH. Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells. J Biol Chem 2007;282:9834-45.
13. Hobson JP, Liu S, Rono B, Leppla SH, Bugge TH. Imaging specific cell-surface proteolytic activity in single living cells. Nat Methods 2006;3:259-61.
14. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res 2000;60:6061-7.
15. Arora N, Klimpel K, Singh Y, Leppla S. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem 1992;267:15542-8.
16. Wong L, Suh DY, FrankelAE. Toxin conjugate therapy of cancer. J Seminoncol2005;8:591 -5.
17. Sharma A, Tran MA, Liang S, et al. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 2006;66:8200-9.
18. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008;59:429-42.
19. White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007;25:4445-51.
20. Hofmann U, Westphal J, Van Muijen G, Ruiter D. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000;115:337-44.
21. Hornebeck W, Emonard H, Monboisse J, Bellon G. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol2002;12:231-41.
22. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
23. Ha SD, Ng D, Pelech S, Kim SO. Critical role of PI3-K/Akt/GSK-3β signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and MEK cleavage in macrophages. J Biol Chem 2007;282:36230-9.
24. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006;12:2301-7s.
25. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122:337-41.
26. Alfano RW, Leppla SH, Bugge TH, Duesbery NS, Frankel AE. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy. Cell Cycle 2008;7. Epub ahead of print.
27. Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63:3955-7.
28. Simonetti O, Lucarini G, Brancorsini D, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 2002;95:1963-70.
29. Spittle C, Ward MR, Nathanson KL, et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 2007;9:464-71.
30. Smalley K, Contractor R, Haass N, et al. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer 2007;96:445-9.